MX2021011943A - Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. - Google Patents

Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Info

Publication number
MX2021011943A
MX2021011943A MX2021011943A MX2021011943A MX2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A
Authority
MX
Mexico
Prior art keywords
treatment
urothelial carcinoma
tyrosine kinase
kinase inhibitors
fgfr
Prior art date
Application number
MX2021011943A
Other languages
English (en)
Inventor
Porre Peter Marie Z De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021011943A publication Critical patent/MX2021011943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Se describen métodos de tratamiento de carcinoma urotelial con una especialidad farmacéutica aprobada que contiene un inhibidor del receptor de factor de crecimiento de fibroblastos (FGFR); también se describen métodos de venta u oferta para la venta de una especialidad farmacéutica que contiene un inhibidor de receptor de factor de crecimiento de fibroblastos (FGFR).
MX2021011943A 2019-03-29 2020-03-27 Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. MX2021011943A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
US201962833395P 2019-04-12 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
MX2021011943A true MX2021011943A (es) 2021-11-03

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011943A MX2021011943A (es) 2019-03-29 2020-03-27 Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Country Status (13)

Country Link
US (1) US20220175768A1 (es)
EP (1) EP3946340A1 (es)
JP (1) JP2022527482A (es)
KR (1) KR20210143878A (es)
CN (1) CN113645975A (es)
AU (1) AU2020253054A1 (es)
CA (1) CA3130773A1 (es)
IL (1) IL286727A (es)
JO (1) JOP20210260A1 (es)
MA (1) MA55486A (es)
MX (1) MX2021011943A (es)
SG (1) SG11202109854RA (es)
WO (1) WO2020201138A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023064830A1 (en) 2021-10-12 2023-04-20 Taris Biomedical Llc Erdafitinib formulations and systems for intravesical administration
TW202400174A (zh) 2022-02-18 2024-01-01 美商塔里斯生物醫學有限責任公司 用於膀胱內施用的Erdafitinib調配物及滲透系統

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
MX2017003954A (es) 2014-09-26 2017-12-14 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr.
PT3576740T (pt) * 2017-12-20 2023-08-18 Janssen Pharmaceutica Nv Tratamento de cancro

Also Published As

Publication number Publication date
KR20210143878A (ko) 2021-11-29
CA3130773A1 (en) 2020-10-08
JOP20210260A1 (ar) 2023-01-30
WO2020201138A1 (en) 2020-10-08
US20220175768A1 (en) 2022-06-09
MA55486A (fr) 2022-02-09
JP2022527482A (ja) 2022-06-02
AU2020253054A1 (en) 2021-09-30
CN113645975A (zh) 2021-11-12
SG11202109854RA (en) 2021-10-28
IL286727A (en) 2021-10-31
EP3946340A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
CA2983481A1 (en) Janus kinase inhibitor
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2016010106A (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2021011943A (es) Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2020011344A (es) Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
MX2021013602A (es) Inhibidores de jak.
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
NZ745936A (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
EA202192643A1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
MX2022001702A (es) Inhibidores de jak.
MX2022005991A (es) Farmaco combinado.
MX2023005716A (es) Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck).
MX2021007853A (es) Compuestos de tienopiridinona.
EP3923947A4 (en) FGFR INHIBITORS FOR THE TREATMENT OF CANCER